About HUMANETICS CORPORATION
Humanetics is a privately held, advanced clinical-stage pharmaceutical company focused on developing drugs to protect and treat against bodily harm caused by exposure to radiation, chemical agents, and biological threats. The company's flagship drug, BIO 300, was initially developed by the U.S. Department of Defense and has been expanded for use in cancer radiation therapy and pulmonary inflammation.
Development of drugs to protect against radiation, chemical agents, and biological threatsClinical-stage pharmaceutical developmentExpansion of drug use from military applications to cancer radiation therapy and pulmonary inflammationActive clinical programs supported by four open Investigational New Drug (IND) applications
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| IGF::OT::IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROS | Department of Health and Human Services | $10.3M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to HUMANETICS CORPORATION right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.